董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James M. Hindman | 男 | Director | 66 | 14.99万美元 | 35.14 | 2026-11-19 |
| Chan W. Galbato | 男 | Director | 63 | 14.03万美元 | 10.66 | 2026-11-19 |
| Stephen La Neve | 男 | President, Chief Executive Officer and Director | 67 | 511.45万美元 | 68.74 | 2026-11-19 |
| Steven F. Mayer | 男 | Director | 66 | 288.10万美元 | 160.22 | 2026-11-19 |
| Richard A. Meier | 男 | Director | 66 | 未披露 | 未持股 | 2026-11-19 |
| Joseph E. Whitters | 男 | Chairman of the Board | 68 | 18.86万美元 | 72.43 | 2026-11-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ali Pervaiz | 男 | Senior Vice President, Chief Financial Officer | 46 | 58.90万美元 | 48.00 | 2026-11-19 |
| Stephen La Neve | 男 | President, Chief Executive Officer and Director | 67 | 511.45万美元 | 68.74 | 2026-11-19 |
| Paul Miele | 男 | Senior Vice President, Chief Commercial Officer | 44 | 69.41万美元 | 未持股 | 2026-11-19 |
董事简历
中英对照 | 中文 | 英文- James M. Hindman
-
James M. Hindman，自2019年9月起担任Accuray Incorporated董事会成员。Hindman先生曾于1984年至2015年3月在眼力健制药公司（“Allergan”）担任多个职位，该公司是一家多专业的医疗保健公司，于2015年被Actavis PLC收购，在该公司担任的职务越来越重要，包括最近担任的财务和业务发展执行副总裁，以及2014年8月至2015年3月担任首席财务官。Hindman先生于2002年3月至2014年8月在Allergan担任财务、风险和投资者关系高级副总裁。从1984年至2002年，Hindman先生在Allergan担任过多个其他财务职位，包括高级副总裁、财务和财务总监；财务副总裁；财务规划和分析副总裁；助理公司财务总监。Hindman先生目前担任私营医疗器械公司Aatru Medical，LLC的董事会成员。在过去五年中，Hindman先生于2016年6月至2021年6月担任上市生物技术公司Millendo Therapeutics, Inc.的董事会成员，于2018年8月至2019年12月担任公共临床阶段医学皮肤病学和美学公司Sienna Biopharmaceuticals, Inc.的董事会成员，于2020年6月至2023年3月担任私营生物制药公司Urovant Sciences，Inc.的董事会成员，并于2021年7月至2024年担任专门开发内分泌和代谢疾病治疗性多肽的私营公司Amolyt Pharma SAS的董事会成员。还自2015年7月起为上市生物技术公司Cidara Therapeutics, Inc.提供财务咨询服务，并于2017年12月至2018年12月为民营生物技术公司RANI Therapeutics Holdings，Inc.提供财务咨询服务。Hindman先生拥有Loyola Marymount大学会计学学士学位和Pepperdine大学工商管理硕士学位。他是加利福尼亚州的注册会计师（非在职）。
James M. Hindman has served as a member of Board since September 2019. Mr. Hindman served in vario positions at Allergan, Inc. ("Allergan"), a multi specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Biness Development, and Chief Financial Officer from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021; Sienna Biopharmaceuticals, Inc., a public clinical stage medical dermatology and aesthetics company, from August 2018 to December 2019; Urovant Sciences, Inc., a private biopharmaceutical company, from June 2020 to March 2023; and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease, from July 2021 to July 2024. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a private biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive). - James M. Hindman，自2019年9月起担任Accuray Incorporated董事会成员。Hindman先生曾于1984年至2015年3月在眼力健制药公司（“Allergan”）担任多个职位，该公司是一家多专业的医疗保健公司，于2015年被Actavis PLC收购，在该公司担任的职务越来越重要，包括最近担任的财务和业务发展执行副总裁，以及2014年8月至2015年3月担任首席财务官。Hindman先生于2002年3月至2014年8月在Allergan担任财务、风险和投资者关系高级副总裁。从1984年至2002年，Hindman先生在Allergan担任过多个其他财务职位，包括高级副总裁、财务和财务总监；财务副总裁；财务规划和分析副总裁；助理公司财务总监。Hindman先生目前担任私营医疗器械公司Aatru Medical，LLC的董事会成员。在过去五年中，Hindman先生于2016年6月至2021年6月担任上市生物技术公司Millendo Therapeutics, Inc.的董事会成员，于2018年8月至2019年12月担任公共临床阶段医学皮肤病学和美学公司Sienna Biopharmaceuticals, Inc.的董事会成员，于2020年6月至2023年3月担任私营生物制药公司Urovant Sciences，Inc.的董事会成员，并于2021年7月至2024年担任专门开发内分泌和代谢疾病治疗性多肽的私营公司Amolyt Pharma SAS的董事会成员。还自2015年7月起为上市生物技术公司Cidara Therapeutics, Inc.提供财务咨询服务，并于2017年12月至2018年12月为民营生物技术公司RANI Therapeutics Holdings，Inc.提供财务咨询服务。Hindman先生拥有Loyola Marymount大学会计学学士学位和Pepperdine大学工商管理硕士学位。他是加利福尼亚州的注册会计师（非在职）。
- James M. Hindman has served as a member of Board since September 2019. Mr. Hindman served in vario positions at Allergan, Inc. ("Allergan"), a multi specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Biness Development, and Chief Financial Officer from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021; Sienna Biopharmaceuticals, Inc., a public clinical stage medical dermatology and aesthetics company, from August 2018 to December 2019; Urovant Sciences, Inc., a private biopharmaceutical company, from June 2020 to March 2023; and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease, from July 2021 to July 2024. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a private biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive).
- Chan W. Galbato
-
Chan W. Galbato自2025年3月起担任私人投资公司Barington Capital Group，LP的高级顾问，自2025年8月起担任咨询公司Alvarez Marsal Holdings，LLC的高级顾问。Previoly，他曾于2012年至2024年担任私人投资公司Cerber Capital Management的全球运营平台Cerber Operations and Advisory Company，LLC的首席执行官。在2009年加入Cerber之前，Galbato先生曾担任全球科技公司Invesys plc的Controls Group总裁兼首席执行官。在此之前，他曾担任家得宝的服务和公司商业分销部门总裁；Armstrong World Indtries的一个部门Armstrong Floor Products的总裁兼首席执行官；合资初创公司Choice Parts的首席执行官；以及GE Capital旗下公司Coregis Insurance Company的总裁兼首席执行官。他在通用电气公司工作了十几年，在其多个工业部门（包括运输系统、飞机发动机、医疗系统和设备）担任过多个运营和财务领导职务。Galbato先生自2025年5月以来，曾在多家公司的董事会、审计委员会、提名和治理委员会、薪酬委员会、财务委员会和技术委员会任职，这些公司包括上市的工程和制造公司The Eastern Company，NFi Group Inc.，一家上市的跨国b制造商，于2025年1月至2025年4月；丨艾伯森公司，Inc.，一家上市的食品和药品零售公司，于2021年4月至2024年10月；Blue Bird Corporation，一家上市的学校BE和特种车辆制造商，于2015年2月至2023年4月；Autob，Inc.，上市的汽车工业数字营销公司，2019年1月至2022年5月；以及上市的化妆品和美容公司雅芳产品有限公司,2016年3月至2020年1月。Galbato先生拥有纽约州立大学经济学学士学位和芝加哥大学工商管理硕士学位。
Chan W. Galbato has been Senior Advisor to Barington Capital Group, LP, a private investment firm, since March 2025, and Alvarez Marsal Holdings, LLC, a consulting firm, since August 2025. Previoly, he was the Chief Executive Officer of Cerber Operations and Advisory Company, LLC, the global operating platform of Cerber Capital Management, a private investment company, from 2012 to 2024. Prior to joining Cerber in 2009, Mr. Galbato served as President and Chief Executive Officer of the Controls Group of Invesys plc, a global technology company. Prior to that, he served as President of Services and of the commercial distribution arm of companies for The Home Depot; President and Chief Executive Officer of Armstrong Floor Products, a division of Armstrong World Indtries; Chief Executive Officer of Choice Parts, a joint venture start up; and President and Chief Executive Officer of Coregis Insurance Company, a GE Capital company. He spent fteen years with General Electric Company, holding several operating and finance leadership positions within their vario indtrial divisions (including Transportation Systems, Aircraft Engines, Medical Systems and Appliances). Mr. Galbato has served on the boards of directors, audit committees, nominating and governance committees, compensation committees, finance committees and technology committees of vario companies, including The Eastern Company, a publicly traded engineering and manufacturing company, since May 2025, NFI Group Inc., a publicly traded multinational b manufacturer, from January 2025 to April 2025; Albertsons Companies, Inc., a publicly traded food and drug retail company, from April 2021 to October 2024; Blue Bird Corporation, a publicly traded manufacturer of school bes and specialty vehicles, from February 2015 to April 2023; Autob, Inc., a publicly traded digital marketing company for the automotive industry, from January 2019 to May 2022; and Avon Products, Inc., a publicly traded cosmetics and beauty company, from March 2016 to January 2020. Mr. Galbato holds a B.A. in Economics from the State University of New York and an M.B.A. from the University of Chicago. - Chan W. Galbato自2025年3月起担任私人投资公司Barington Capital Group，LP的高级顾问，自2025年8月起担任咨询公司Alvarez Marsal Holdings，LLC的高级顾问。Previoly，他曾于2012年至2024年担任私人投资公司Cerber Capital Management的全球运营平台Cerber Operations and Advisory Company，LLC的首席执行官。在2009年加入Cerber之前，Galbato先生曾担任全球科技公司Invesys plc的Controls Group总裁兼首席执行官。在此之前，他曾担任家得宝的服务和公司商业分销部门总裁；Armstrong World Indtries的一个部门Armstrong Floor Products的总裁兼首席执行官；合资初创公司Choice Parts的首席执行官；以及GE Capital旗下公司Coregis Insurance Company的总裁兼首席执行官。他在通用电气公司工作了十几年，在其多个工业部门（包括运输系统、飞机发动机、医疗系统和设备）担任过多个运营和财务领导职务。Galbato先生自2025年5月以来，曾在多家公司的董事会、审计委员会、提名和治理委员会、薪酬委员会、财务委员会和技术委员会任职，这些公司包括上市的工程和制造公司The Eastern Company，NFi Group Inc.，一家上市的跨国b制造商，于2025年1月至2025年4月；丨艾伯森公司，Inc.，一家上市的食品和药品零售公司，于2021年4月至2024年10月；Blue Bird Corporation，一家上市的学校BE和特种车辆制造商，于2015年2月至2023年4月；Autob，Inc.，上市的汽车工业数字营销公司，2019年1月至2022年5月；以及上市的化妆品和美容公司雅芳产品有限公司,2016年3月至2020年1月。Galbato先生拥有纽约州立大学经济学学士学位和芝加哥大学工商管理硕士学位。
- Chan W. Galbato has been Senior Advisor to Barington Capital Group, LP, a private investment firm, since March 2025, and Alvarez Marsal Holdings, LLC, a consulting firm, since August 2025. Previoly, he was the Chief Executive Officer of Cerber Operations and Advisory Company, LLC, the global operating platform of Cerber Capital Management, a private investment company, from 2012 to 2024. Prior to joining Cerber in 2009, Mr. Galbato served as President and Chief Executive Officer of the Controls Group of Invesys plc, a global technology company. Prior to that, he served as President of Services and of the commercial distribution arm of companies for The Home Depot; President and Chief Executive Officer of Armstrong Floor Products, a division of Armstrong World Indtries; Chief Executive Officer of Choice Parts, a joint venture start up; and President and Chief Executive Officer of Coregis Insurance Company, a GE Capital company. He spent fteen years with General Electric Company, holding several operating and finance leadership positions within their vario indtrial divisions (including Transportation Systems, Aircraft Engines, Medical Systems and Appliances). Mr. Galbato has served on the boards of directors, audit committees, nominating and governance committees, compensation committees, finance committees and technology committees of vario companies, including The Eastern Company, a publicly traded engineering and manufacturing company, since May 2025, NFI Group Inc., a publicly traded multinational b manufacturer, from January 2025 to April 2025; Albertsons Companies, Inc., a publicly traded food and drug retail company, from April 2021 to October 2024; Blue Bird Corporation, a publicly traded manufacturer of school bes and specialty vehicles, from February 2015 to April 2023; Autob, Inc., a publicly traded digital marketing company for the automotive industry, from January 2019 to May 2022; and Avon Products, Inc., a publicly traded cosmetics and beauty company, from March 2016 to January 2020. Mr. Galbato holds a B.A. in Economics from the State University of New York and an M.B.A. from the University of Chicago.
- Stephen La Neve
-
Stephen La Neve，曾担任Globus医疗 Inc.创伤和关节重建业务部门总裁兼Globus医疗日本K.K.（NYSE：GMED）总裁、Bone Biologics CorporationTERM3（NASDAQ：BBLG）首席执行官兼董事会成员、Becton Dickinson Preanalytical Systems（NYSE：BDX）全球总裁，以及美敦力脊柱和生物制剂部门（NYSE：MDT）全球部门总裁。
Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT). - Stephen La Neve，曾担任Globus医疗 Inc.创伤和关节重建业务部门总裁兼Globus医疗日本K.K.（NYSE：GMED）总裁、Bone Biologics CorporationTERM3（NASDAQ：BBLG）首席执行官兼董事会成员、Becton Dickinson Preanalytical Systems（NYSE：BDX）全球总裁，以及美敦力脊柱和生物制剂部门（NYSE：MDT）全球部门总裁。
- Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).
- Steven F. Mayer
-
Steven F. Mayer自2002年11月起担任Cerberus Capital Management，L.P.和/或Cerberus California，LLC及其前身实体的高级董事总经理或董事总经理，还担任Cerberus全球私募股权部门的联席主管。在2002年加入Cerberus之前，自2001年起，Mayer先生担任Gores Technology集团执行董事总经理。在加入Gores之前，从1996年到2001年，Mayer先生担任Libra Capital Partners，L.P.的董事总经理。从1994年到1996年，Mayer先生担任Aries Capital Group，LLC的董事总经理，该公司是他与他人共同创立的一家私募股权投资公司。从1992年到1994年，Mayer先生是Apollo Advisors，L.P.和Lion Advisors，L.P.附属私人投资公司的负责人。在此之前，Mayer先生是Sullivan & Cromwell的一名律师。Mayer先生是Avon Products, Inc. NYSE：AVP、GRIFOLS, S.A.（NASDAQ：GRFS）、New Avon，LLC、Spyglass Entertainment Holdings，LLC、Staples Solutions，B.V。、Starrus Holdings Limited和YP Holdings，LLC的董事会成员。Mayer先生以优异成绩获得普林斯顿大学的学士学位，并以优异成绩获得哈佛法学院的法学博士学位。
Steven F. Mayer has served as Chairman of the Operations Advisory Counsel and Senior Advisor to the private credit group of TCW, a $200 billion investment group, since 2023; a senior strategic advisor to Red Arts Capital, a private equity firm focused on supply chain investments, since 2024; Chairman and Co founder of 9Squared, LLC, a technology company, since 2023; and Chief Executive Officer of Dedication Capital, LLC, a privately held investment vehicle, since 2018. Previoly, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, from 2022 to 2023 and Senior Managing Director, Co Head of Global Private Equity, and Chairman of the Investment Committee of Cerber Capital Management, L.P. from 2002 to 2018. Mr. Mayer currently serves on the Board of Directors of Pace Indtries Holdings, LLC, a privately held die cast manufacturer in North America; the holding company of Landmark Structures I, LP, a privately held engineering and contracting company in North America; and 9Squared LLC, an early stage, privately held technology company, and previoly served on the Boards of Directors of Grifols, SA, a global healthcare company, from June 2011 to February 2023 and Knowles Corporation, a manufacturer of specialty electronic components, from May 2019 through October 2019. Mr. Mayer holds a J.D. from Harvard Law School and a B.A. in public and international affairs from Princeton University. Mr. Mayer was appointed to Board in connection with the Company's debt refinancing in June 2025 pursuant to the terms of the Governance Agreement dated June 6, 2025, by and beten the Company and TCW Asset Management Company LLC. - Steven F. Mayer自2002年11月起担任Cerberus Capital Management，L.P.和/或Cerberus California，LLC及其前身实体的高级董事总经理或董事总经理，还担任Cerberus全球私募股权部门的联席主管。在2002年加入Cerberus之前，自2001年起，Mayer先生担任Gores Technology集团执行董事总经理。在加入Gores之前，从1996年到2001年，Mayer先生担任Libra Capital Partners，L.P.的董事总经理。从1994年到1996年，Mayer先生担任Aries Capital Group，LLC的董事总经理，该公司是他与他人共同创立的一家私募股权投资公司。从1992年到1994年，Mayer先生是Apollo Advisors，L.P.和Lion Advisors，L.P.附属私人投资公司的负责人。在此之前，Mayer先生是Sullivan & Cromwell的一名律师。Mayer先生是Avon Products, Inc. NYSE：AVP、GRIFOLS, S.A.（NASDAQ：GRFS）、New Avon，LLC、Spyglass Entertainment Holdings，LLC、Staples Solutions，B.V。、Starrus Holdings Limited和YP Holdings，LLC的董事会成员。Mayer先生以优异成绩获得普林斯顿大学的学士学位，并以优异成绩获得哈佛法学院的法学博士学位。
- Steven F. Mayer has served as Chairman of the Operations Advisory Counsel and Senior Advisor to the private credit group of TCW, a $200 billion investment group, since 2023; a senior strategic advisor to Red Arts Capital, a private equity firm focused on supply chain investments, since 2024; Chairman and Co founder of 9Squared, LLC, a technology company, since 2023; and Chief Executive Officer of Dedication Capital, LLC, a privately held investment vehicle, since 2018. Previoly, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, from 2022 to 2023 and Senior Managing Director, Co Head of Global Private Equity, and Chairman of the Investment Committee of Cerber Capital Management, L.P. from 2002 to 2018. Mr. Mayer currently serves on the Board of Directors of Pace Indtries Holdings, LLC, a privately held die cast manufacturer in North America; the holding company of Landmark Structures I, LP, a privately held engineering and contracting company in North America; and 9Squared LLC, an early stage, privately held technology company, and previoly served on the Boards of Directors of Grifols, SA, a global healthcare company, from June 2011 to February 2023 and Knowles Corporation, a manufacturer of specialty electronic components, from May 2019 through October 2019. Mr. Mayer holds a J.D. from Harvard Law School and a B.A. in public and international affairs from Princeton University. Mr. Mayer was appointed to Board in connection with the Company's debt refinancing in June 2025 pursuant to the terms of the Governance Agreement dated June 6, 2025, by and beten the Company and TCW Asset Management Company LLC.
- Richard A. Meier
-
Richard A. Meier自2013年3月起开始担任 Owens & Minor公司（一家执行医疗保健服务的全球供应商）副总裁和首席财务官。自2006年起担任BioMarin制药有限公司董事；2010年3月开始担任审计完委员会主席。从2010年1月到2012年3月担任Teleflex（一家医疗设备的全球供应商）执行副总裁和首席财务官。之前他曾于2007年2月担任Advanced Medical Optics公司总裁和首席运营官，直到2009年4月公司被雅培公司 收购。AMO是眼科手术界最大的公司之一。从2006年4月到2007年2月他担任AMO运营部执行副总裁；全球眼部护理总裁和首席财务官。从2004年2月到2006年4月他担任AMO运营部和金融部执行副总裁和首席财务官。从2002年4月到2004年2月担任公司副总裁和首席财务官。加入AMO之前，他从1999年10月开始担任Valeant制药公司执行副总裁和首席财务官；从1998年到1999年10月担任高级副总裁和风险官。加入Valeant之前，他在纽约一家投资银行-- Schroder 公司担任执行官。加入 Schroder 公司之前，他在所罗门美邦公司、汉诺威制造公司、澳大利亚资本公司以及Greyhound Lines公司担任多个金融和银行职位。他是普林斯顿大学毕业生，持有经济学学士学位。
Richard A. Meier joined Biomarin Pharmaceutical Inc.'s Board in December 2006 and serves as the Chair of the Audit Committee and has served as Biomarin Pharmaceutical Inc. Lead Independent Director since June 2015. In March of 2013 Mr. Meier joined Owens & Minor, Inc., a global healthcare services company, as Executive Vice President and Chief Financial Officer, and was promoted to President-International and Executive Vice President and Chief Financial Officer, as of July 2015. From January 2010 through March 2012 Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company. From November 2007 to May 2009 Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Between April 2002 and November 2007 Mr. Meier served continuously as Advanced Medical Optics'Chief Financial Officer, while serving in a variety of additional senior operating roles. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. formerly ICN Pharmaceuticals, Inc., from October 1999 to April 2002 and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining ICN Pharmaceuticals, Inc., Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a Director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016 where he also served on both the Governance and Audit Committees. Mr. Meier holds a B.A. in economics from Princeton University. - Richard A. Meier自2013年3月起开始担任 Owens & Minor公司（一家执行医疗保健服务的全球供应商）副总裁和首席财务官。自2006年起担任BioMarin制药有限公司董事；2010年3月开始担任审计完委员会主席。从2010年1月到2012年3月担任Teleflex（一家医疗设备的全球供应商）执行副总裁和首席财务官。之前他曾于2007年2月担任Advanced Medical Optics公司总裁和首席运营官，直到2009年4月公司被雅培公司 收购。AMO是眼科手术界最大的公司之一。从2006年4月到2007年2月他担任AMO运营部执行副总裁；全球眼部护理总裁和首席财务官。从2004年2月到2006年4月他担任AMO运营部和金融部执行副总裁和首席财务官。从2002年4月到2004年2月担任公司副总裁和首席财务官。加入AMO之前，他从1999年10月开始担任Valeant制药公司执行副总裁和首席财务官；从1998年到1999年10月担任高级副总裁和风险官。加入Valeant之前，他在纽约一家投资银行-- Schroder 公司担任执行官。加入 Schroder 公司之前，他在所罗门美邦公司、汉诺威制造公司、澳大利亚资本公司以及Greyhound Lines公司担任多个金融和银行职位。他是普林斯顿大学毕业生，持有经济学学士学位。
- Richard A. Meier joined Biomarin Pharmaceutical Inc.'s Board in December 2006 and serves as the Chair of the Audit Committee and has served as Biomarin Pharmaceutical Inc. Lead Independent Director since June 2015. In March of 2013 Mr. Meier joined Owens & Minor, Inc., a global healthcare services company, as Executive Vice President and Chief Financial Officer, and was promoted to President-International and Executive Vice President and Chief Financial Officer, as of July 2015. From January 2010 through March 2012 Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company. From November 2007 to May 2009 Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Between April 2002 and November 2007 Mr. Meier served continuously as Advanced Medical Optics'Chief Financial Officer, while serving in a variety of additional senior operating roles. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. formerly ICN Pharmaceuticals, Inc., from October 1999 to April 2002 and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining ICN Pharmaceuticals, Inc., Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a Director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016 where he also served on both the Governance and Audit Committees. Mr. Meier holds a B.A. in economics from Princeton University.
- Joseph E. Whitters
-
Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College. - Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
- Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.
高管简历
中英对照 | 中文 | 英文- Ali Pervaiz
Ali Pervaiz自2022年5月起担任高级副总裁、首席财务官。Previoly，Pervaiz先生于2020年8月至2022年5月担任全球商业运营副总裁。在加入公司之前，Pervaiz先生曾任职于GE Healthcare，该公司是一家全球医疗技术、药物诊断和数字解决方案创新者，也是通用电气公司的子公司，担任高级财务和运营领导职务超过15年，最近担任执行–利润率增长PMO Leader，于2018年9月至2020年1月期间专注于Global Imaging BINSE的利润率扩张，执行– Advance Leader于2017年1月至2018年9月期间专注于商业战略与财务转型。在GE医疗集团任职期间，曾入选公司审计人员项目并毕业的Pervaiz先生还曾在GE医疗集团担任商业诊断成像设备和商业生命支持解决方案binesses的BINES部门首席财务官职务。Pervaiz先生拥有芝加哥大学Booth Biness学院金融和运营FOC的工商管理硕士学位、威斯康星医学院的医疗技术管理硕士学位和马凯特大学的学士学位。
Ali Pervaiz has served as Senior Vice President, Chief Financial Officer since May 2022. Previoly, Mr. Pervaiz served as Vice President, Global Commercial Operations from August 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging biness from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previoly held biness unit Chief Financial Officer roles at GE Healthcare for the Commercial Diagnostic Imaging Equipment and Commercial Life Support Solutions binesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Biness with foc on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.- Ali Pervaiz自2022年5月起担任高级副总裁、首席财务官。Previoly，Pervaiz先生于2020年8月至2022年5月担任全球商业运营副总裁。在加入公司之前，Pervaiz先生曾任职于GE Healthcare，该公司是一家全球医疗技术、药物诊断和数字解决方案创新者，也是通用电气公司的子公司，担任高级财务和运营领导职务超过15年，最近担任执行–利润率增长PMO Leader，于2018年9月至2020年1月期间专注于Global Imaging BINSE的利润率扩张，执行– Advance Leader于2017年1月至2018年9月期间专注于商业战略与财务转型。在GE医疗集团任职期间，曾入选公司审计人员项目并毕业的Pervaiz先生还曾在GE医疗集团担任商业诊断成像设备和商业生命支持解决方案binesses的BINES部门首席财务官职务。Pervaiz先生拥有芝加哥大学Booth Biness学院金融和运营FOC的工商管理硕士学位、威斯康星医学院的医疗技术管理硕士学位和马凯特大学的学士学位。
- Ali Pervaiz has served as Senior Vice President, Chief Financial Officer since May 2022. Previoly, Mr. Pervaiz served as Vice President, Global Commercial Operations from August 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging biness from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previoly held biness unit Chief Financial Officer roles at GE Healthcare for the Commercial Diagnostic Imaging Equipment and Commercial Life Support Solutions binesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Biness with foc on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.
- Stephen La Neve
Stephen La Neve，曾担任Globus医疗 Inc.创伤和关节重建业务部门总裁兼Globus医疗日本K.K.（NYSE：GMED）总裁、Bone Biologics CorporationTERM3（NASDAQ：BBLG）首席执行官兼董事会成员、Becton Dickinson Preanalytical Systems（NYSE：BDX）全球总裁，以及美敦力脊柱和生物制剂部门（NYSE：MDT）全球部门总裁。
Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).- Stephen La Neve，曾担任Globus医疗 Inc.创伤和关节重建业务部门总裁兼Globus医疗日本K.K.（NYSE：GMED）总裁、Bone Biologics CorporationTERM3（NASDAQ：BBLG）首席执行官兼董事会成员、Becton Dickinson Preanalytical Systems（NYSE：BDX）全球总裁，以及美敦力脊柱和生物制剂部门（NYSE：MDT）全球部门总裁。
- Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).
- Paul Miele
Paul Miele，于2024年9月至2026年4月在跨国医疗保健公司强生的医疗器械部门强生 MedTech担任业务部门负责人兼Monarch机器人平台总经理。在此之前，他于2016年6月至2023年7月任职于全球肌肉骨骼技术公司Globus医疗，曾担任多个高级销售职位，包括最近于2022年7月至2023年7月担任美洲亚太区销售副总裁。在此之前，他曾在直觉外科、MPathy Medical、Cook Medical和礼来 & Company担任多个与销售相关的职位。Miele先生拥有东北大学金融和市场营销学士学位。
Paul Miele,served as Business Unit Leader & General Manager of the Monarch Robotic Platform at Johnson & Johnson MedTech, the medical device division of the multinational healthcare company, Johnson & Johnson, from September 2024 to April 2026. Prior to that, he was at Globus Medical, a global musculoskeletal technology company, from June 2016 to July 2023, where he served in various senior-level sales positions, including most recently as Vice President Sales, Americas APAC from July 2022 to July 2023. Prior to that he served in various sales-related positions at Intuitive Surgical, Mpathy Medical, Cook Medical and Eli Lilly & Company. Mr. Miele holds a B.S. in Finance and Marketing from Northeastern University.- Paul Miele，于2024年9月至2026年4月在跨国医疗保健公司强生的医疗器械部门强生 MedTech担任业务部门负责人兼Monarch机器人平台总经理。在此之前，他于2016年6月至2023年7月任职于全球肌肉骨骼技术公司Globus医疗，曾担任多个高级销售职位，包括最近于2022年7月至2023年7月担任美洲亚太区销售副总裁。在此之前，他曾在直觉外科、MPathy Medical、Cook Medical和礼来 & Company担任多个与销售相关的职位。Miele先生拥有东北大学金融和市场营销学士学位。
- Paul Miele,served as Business Unit Leader & General Manager of the Monarch Robotic Platform at Johnson & Johnson MedTech, the medical device division of the multinational healthcare company, Johnson & Johnson, from September 2024 to April 2026. Prior to that, he was at Globus Medical, a global musculoskeletal technology company, from June 2016 to July 2023, where he served in various senior-level sales positions, including most recently as Vice President Sales, Americas APAC from July 2022 to July 2023. Prior to that he served in various sales-related positions at Intuitive Surgical, Mpathy Medical, Cook Medical and Eli Lilly & Company. Mr. Miele holds a B.S. in Finance and Marketing from Northeastern University.